Piotroski F-score
Failed
2 checks could not be answered: a figure either filed year needs is missing, not evidence either way.
KROS reported revenue of $243.86M and net income of $87.01M in FY2025.
| Fiscal year | Revenue | Net income |
|---|---|---|
| 2025 | $243.86M | $87.01M |
| 2024 | $3.55M | −$187.35M |
| 2023 | $151K | −$152.99M |
4 more years are on Measure
Free, no card, and it does not expire. See what the paid plans add
Also filed under Biotechnology, ranked by how closely they sit beside KROS.
KROS is among the largest companies matching:
Cash flow breakdown
What the business generated, and where it went
Operating cash flow
$107.51M 2025
Cash generated by the business itself
Free cash flow
$105.95M 2025
Operating cash flow minus capital expenditure
Capital expenditure
$1.55M 2025
Spending on property, plant and equipment
KROS generated $107.51M of operating cash flow. Each figure below is what it did with that, as reported on the same statement.
Reinvested in the business
Spent on its own shares
A non-cash cost, added back above
As reported in the company's own annual filings.
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | $107.51M | −$160.87M | −$124.51M | −$70.06M | −$62.15M | −$36.89M | −$16M |
| Capital expenditure | $1.55M | $1.93M | $2.46M | $1.24M | $1.02M | $294K | $271K |
| Free cash flow | $105.95M | −$162.8M | −$126.97M | −$71.3M | −$63.17M | −$37.19M | −$16.27M |
| Stock-based compensation | $28.7M |
Financial statements
Every figure below is this company’s, as filed. Measure draws them: 7 years and 30 quarters plotted to scale, on the income statement, balance sheet and cash flow, plus the ratio and estimate sections this page does not carry.
Free, no card, and it does not expire. See what the paid plans add
As reported in the company's own annual filings.
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $243.86M | $3.55M | $151K | $0 | $20.1M | $0 | $10M |
| Research and development | $129.64M | $173.63M | $135.26M | $87.27M | $55.14M | $33.86M | $17.38M |
| Selling, general and administrative | $46.85M | $40.75M | $34.83M | $27.53M | $21.33M | $12.8M | $3.18M |
| Operating income | $67.57M | −$210.83M | −$169.94M | −$114.79M | −$56.37M | −$46.66M | −$10.56M |
| Net income | $87.01M | −$187.35M | −$152.99M | −$104.68M | −$58.74M | −$45.36M | −$12.34M |
| Diluted EPS | $2.30 | -$5.00 | -$5.20 | -$4.15 | -$2.52 | -$2.93 | - |
| Diluted shares | 37.86M | 37.44M | 29.45M | 25.24M | 23.33M | 15.51M | - |
| Operating margin | 27.71% | −5938.96% | −112543.71% | - | −280.46% | - | −105.63% |
| Net margin | 35.68% | −5277.55% | −101319.21% | - | −292.26% | - | −123.36% |
Total assets
Plotted to scale onMeasure
Total liabilities
Plotted to scale onMeasure
Cash
Plotted to scale onMeasure
Current assets
Plotted to scale onMeasure
Current liabilities
Plotted to scale onMeasure
As reported in the company's own annual filings.
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Total assets | $338.02M | $615.89M | $370.03M | $306.78M | $255.25M | $269.44M | $10.96M |
| Current assets | $315.43M | $588.89M | $347.29M | $285.77M | $251.44M | $267.73M | $8.93M |
| Cash | $288.86M | $561.38M | $332.36M | $280.38M | $231.37M | $265.99M | $7.14M |
| Total liabilities | $34.89M | $44.33M |
Derived from SEC XBRL filings. Not investment advice.
The assistant answers from what KROS has actually filed: 7 annual reports filed with the SEC, 39 Form 4 filings from the last year and 3 funds that hold it. Every figure in a reply links to the filing it came from, so an answer can be checked rather than believed.
Press one and the answer appears right here on the page, from KROS's filings and figures. One a day without an account; a free account has its own, and no card.
See every filed year for KROS, quarter by quarter.
Ten seconds. No card. Nothing to cancel.
Be told the next time KROS files
Watch KROS and every quarterly and annual report, material 8-K, open-market Form 4 worth a row and tracked manager's change lands in the bell and a daily email. Free.
See all 7 filed years plotted, not just read
Every annual statement KROS has filed is on this page as figures. Drawn to scale, a trend over the whole record is something you can see rather than something you have to add up.
The charts, to scaleMeasure
Catch a turn before the year confirms it
Revenue, margins and cash flow quarter by quarter, where a change in direction shows up first.
Quarterly statementsMeasure
Ask why a number moved, get the filing back
Why a margin moved, where the cash went: answered from KROS's own statements, not a guess.
Free, no card, and it does not expire.
| $34.87M |
| $28.76M |
| $18.68M |
| $11.72M |
| $4.1M |
| $59K |
| Buybacks | $375M | $0 | - | - | - | - | - |
|---|
| $37.81M |
| $29.36M |
| $12.08M |
| $7.72M |
| $10.46M |
| Current liabilities | $20.41M | $27.45M | $24.37M | $16.55M | $11.85M | $7.18M | $4.49M |
|---|
| Temporary equity | - | - | - | - | - | - | $19.94M |
|---|
| Shareholder equity | $303.13M | $571.55M | $332.21M | $277.42M | $243.17M | $261.72M | −$19.45M |
|---|